Thanks a lot for the opportunity. I have two questions. Question one on some indication on the vacuum that had got created because of loss of two molecules. So Yann, specifically for you, what is being done right now to ensure this kind of vacuum does not get created in future? So that is question one I have. And second question I wi ll ask once you respond to this. It i s for Umang. My second question is for actually Umang. Yann D’Herve: That is true, we mentioned it several times. I mean, we have a dip because of the high concentration in a few molecules and the fact that some are getting close to becoming generics, right? So what do we do about it, right? In order to bring growth is essentially expansion in term of number of customers and being able to get projects that are later phase in the customer project pipeline to accelerate the recovery. So that i s what we are doing at the moment. We see good traction with strong fun nel that has been multiplied by two essentially in the last six months with regard to small molecule that give us strong hope that we are going in the right direction here.
Okay. And second question for Umang, actually a slightly different question. Since you have joined the organization, have you been able to focus on corporate governance and strengthening the processes or it has not been on your agenda as of now? Why I am asking that in your absence when you are not there, it is coincidental that certain information and certain investor category have co-aligned in that sense. At the peak, some information has got out and some investors have exited and re-entered at the bottom of the stock price and since then the again positive announcements have started. So, it is a request if you look at the strengthening of corporate governance slash information flow which I believe was happening selectively. I could be absolutely wrong and I hope I am wrong. So, if you have not been able to spend time, I would request you to focus on that. That is my second question.